Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases.

Shahzaib Maqbool, Maryam Farhan Baloch, Muhammad Abdul Khaliq Khan, Azeem Khalid, Kiran Naimat
{"title":"Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases.","authors":"Shahzaib Maqbool, Maryam Farhan Baloch, Muhammad Abdul Khaliq Khan, Azeem Khalid, Kiran Naimat","doi":"10.5500/wjt.v14.i1.87532","DOIUrl":null,"url":null,"abstract":"<p><p>Conditioning regimens employed in autologous stem cell transplantation have been proven useful in various hematological disorders and underlying malig nancies; however, despite being efficacious in various instances, negative consequences have also been recorded. Multiple conditioning regimens were extracted from various literature searches from databases like PubMed, Google scholar, EMBASE, and Cochrane. Conditioning regimens for each disease were compared by using various end points such as overall survival (OS), progression free survival (PFS), and leukemia free survival (LFS). Variables were presented on graphs and analyzed to conclude a more efficacious conditioning regimen. In multiple myeloma, the most effective regimen was high dose melphalan (MEL) given at a dose of 200/mg/m<sup>2</sup>. The comparative results of acute myeloid leukemia were presented and the regimens that proved to be at an admirable position were busulfan (BU) + MEL regarding OS and BU + VP16 regarding LFS. In case of acute lymphoblastic leukemia (ALL), BU, fludarabine, and etoposide (BuFluVP) conferred good disease control not only with a paramount improvement in survival rate but also low risk of recurrence. However, for ALL, chimeric antigen receptor (CAR) T cell therapy was preferred in the context of better OS and LFS. With respect to Hodgkin's lymphoma, mitoxantrone (MITO)/MEL overtook carmustine, VP16, cytarabine, and MEL in view of PFS and <i>vice versa</i> regarding OS. Non-Hodgkin's lymphoma patients were administered MITO (60 mg/m<sup>2</sup>) and MEL (180 mg/m<sup>2</sup>) which showed promising results. Lastly, amyloidosis was considered, and the regimen that proved to be competent was MEL 200 (200 mg/m<sup>2</sup>). This review article demonstrates a comparison between various conditioning regimens employed in different diseases.</p>","PeriodicalId":68893,"journal":{"name":"世界移植杂志(英文版)","volume":"14 1","pages":"87532"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10989471/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"世界移植杂志(英文版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5500/wjt.v14.i1.87532","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Conditioning regimens employed in autologous stem cell transplantation have been proven useful in various hematological disorders and underlying malig nancies; however, despite being efficacious in various instances, negative consequences have also been recorded. Multiple conditioning regimens were extracted from various literature searches from databases like PubMed, Google scholar, EMBASE, and Cochrane. Conditioning regimens for each disease were compared by using various end points such as overall survival (OS), progression free survival (PFS), and leukemia free survival (LFS). Variables were presented on graphs and analyzed to conclude a more efficacious conditioning regimen. In multiple myeloma, the most effective regimen was high dose melphalan (MEL) given at a dose of 200/mg/m2. The comparative results of acute myeloid leukemia were presented and the regimens that proved to be at an admirable position were busulfan (BU) + MEL regarding OS and BU + VP16 regarding LFS. In case of acute lymphoblastic leukemia (ALL), BU, fludarabine, and etoposide (BuFluVP) conferred good disease control not only with a paramount improvement in survival rate but also low risk of recurrence. However, for ALL, chimeric antigen receptor (CAR) T cell therapy was preferred in the context of better OS and LFS. With respect to Hodgkin's lymphoma, mitoxantrone (MITO)/MEL overtook carmustine, VP16, cytarabine, and MEL in view of PFS and vice versa regarding OS. Non-Hodgkin's lymphoma patients were administered MITO (60 mg/m2) and MEL (180 mg/m2) which showed promising results. Lastly, amyloidosis was considered, and the regimen that proved to be competent was MEL 200 (200 mg/m2). This review article demonstrates a comparison between various conditioning regimens employed in different diseases.

Abstract Image

Abstract Image

Abstract Image

各种疾病的自体造血干细胞移植调理方案和嵌合抗原受体 T 细胞疗法。
自体干细胞移植中采用的调理方案已被证明对各种血液病和潜在的恶性肿瘤有用;然而,尽管在各种情况下具有疗效,但也有负面影响的记录。我们从PubMed、Google scholar、EMBASE和Cochrane等数据库的各种文献检索中提取了多种调理方案。通过使用各种终点,如总生存期(OS)、无进展生存期(PFS)和无白血病生存期(LFS),对每种疾病的调理方案进行比较。通过图表显示和分析变量,得出了更有效的治疗方案的结论。在多发性骨髓瘤中,最有效的治疗方案是剂量为200/毫克/平方米的大剂量美法仑(MEL)。会上还介绍了急性髓性白血病的比较结果,结果表明,就OS而言,硫酸丁胺(BU)+MEL疗法,就LFS而言,硫酸丁胺(BU)+VP16疗法均处于令人钦佩的地位。就急性淋巴细胞白血病(ALL)而言,丁胺卡那霉素、氟达拉滨和依托泊苷(BuFluVP)不仅能很好地控制疾病,显著提高生存率,而且复发风险低。然而,对于 ALL 而言,嵌合抗原受体(CAR)T 细胞疗法具有更好的 OS 和 LFS,是首选疗法。在霍奇金淋巴瘤方面,米托蒽醌(MITO)/MEL在PFS方面优于卡莫司汀、VP16、阿糖胞苷和MEL,在OS方面则相反。对非霍奇金淋巴瘤患者使用了 MITO(60 毫克/平方米)和 MEL(180 毫克/平方米),结果令人鼓舞。最后,考虑到淀粉样变性,MEL 200(200 毫克/平方米)方案被证明是有效的。这篇综述文章对不同疾病采用的各种治疗方案进行了比较。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
364
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信